Varenicline for Cannabis Use Disorder: What Five Studies Show
Varenicline for cannabis use disorder: A systematic review of five studies involving 299 participants found mixed efficacy and tolerability results. Only one study was rated high quality, and methods were too heterogeneous for meta-analysis. Current…
2026 Review: Cannabinoids in Managing MS Spasticity
This 2026 systematic review evaluates cannabinoids for MS spasticity, finding modest improvements with THC:CBD extracts. Despite low evidence certainty, cannabinoids may aid some patients with MS spasticity as adjunctive therapy. Careful clinical…
What Happens After Cannabis Laws Change? A Review of 176 Policy Studies
Cannabis policy and substance use evidence from 176 quasi-experimental reports shows adult cannabis use often rises after liberalization. Alcohol, tobacco, opioid, and youth outcomes varied by policy and population. The review supports targeted…
Purified CBD and Epilepsy: Insights on Nonseizure Outcomes from New Review
A recent systematic review examined highly purified cannabidiol epilepsy treatment focusing on nonseizure outcomes such as cognition, behavior, and quality of life. The evidence, mainly observational, suggests potential benefits but remains inconclusive…
Cannabis and Parkinson’s Disease: What a New Evidence Review Shows
A recent systematic review evaluated cannabis sativa Parkinsons motor symptoms and found Grade A evidence indicating no motor benefit. This review clarifies cannabis sativa's role in Parkinson's motor symptom treatment. It highlights the need for careful…
Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…
Cannabinoids in Substance Use Disorders: What a New Systematic Review Actually Found
Cannabinoids and substance use disorders were the focus of a 2026 systematic review spanning 97 studies and nearly 42,000 participants. The review found cannabinoids more often relieved short-term symptoms like craving and withdrawal than they improved…
Cannabis Science Evidence Report: Systematic Review and Meta-Analysis
This systematic review and meta-analysis examines the prevalence cannabis use disorder early-onset psychosis, highlighting important clinical and functional impacts. The study synthesizes data from 40 studies involving adolescents with early-onset…
Cannabinoids in Autism, Fragile X, and Rett: What a New Systematic Review Found
A new cannabinoids pediatric autism review examined cannabinoid-based products in autism, Fragile X syndrome, and Rett syndrome. The review found possible behavioral and seizure signals but the evidence remains limited. This systematic review highlights…
GLP-1 Weight Loss Drugs: Male Fertility Safety Evidence
GLP-1 receptor agonist male fertility safety is supported by current evidence showing no adverse effects on reproductive function. Studies indicate these drugs may improve fertility outcomes through metabolic benefits. This reassures clinicians and…